Unique ID issued by UMIN | UMIN000001600 |
---|---|
Receipt number | R000001922 |
Scientific Title | Effect of Pitavastatin on Amelioration for Renal Function in Patients with Chronic Kidney Disease |
Date of disclosure of the study information | 2009/01/20 |
Last modified on | 2014/08/19 21:55:43 |
Effect of Pitavastatin on Amelioration for Renal Function in Patients with Chronic Kidney Disease
effect of PitavaSTatin on Amelioration for Renal function in patients with Chronic Kidney Disease (P-STAR-CKD)
Effect of Pitavastatin on Amelioration for Renal Function in Patients with Chronic Kidney Disease
effect of PitavaSTatin on Amelioration for Renal function in patients with Chronic Kidney Disease (P-STAR-CKD)
Japan |
Hypercholesterolemia patients evaluated inulin clearance with chronic kidney disease (stage 3)
Nephrology |
Others
NO
To evaluate efficiency of statin therapy against GFR by inulin clearance in hypercholesterolemia patients with chronic kidney disease, and to elucidate mechanism of statin for increasing GFR.
Efficacy
Amount of change in inulin clearance
1)Comparison of a percent and amount change in inulin clearance and eGFR among baseline matched CKD stage3 patients who is under medical care in Nagoya University Hospital without statins prescription
2)A percent change in inulin clearance
3)A percent and amount of change in following factors
1.Serum lipid profile (TC, LDL-C, HDL-C, TG)
2.The laboratory parameters (AST, ALT, gamma-GTP, CK, and the other)
3.The laboratory parameters(RBC, WBC, Ht, and the other)
4.The special laboratory parameters (hs-CRP, 8-OHdG, alpha1 globulin, beta2 globulin, creatine)
5.Urinary protein (Urinary albumin)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Pitavastatin 1 mg or 2 mg daily for a period of 6 months
20 | years-old | <= |
80 | years-old | > |
Male and Female
(1)Patients of CKD stage 3 in
stable* phase.
*Stable: Patients whose creatine
levels do not change more than 25% for 1 year.
(2)Hypercholesterolemia patients or patients with serum LDL-C level of 120 mg/dL or more and required a cholesterol lowering agent.
(3)Patients who are over 20 years old and less than 80 years old during observation periods.
(4)Patients who were assessed GFR by inulin clearance within 3 months.
(1)Patients whose creatine levels change more than 25% in past 1 year.
(2)Patients who are planed to change drugs for CKD.
(3)Known hypersensitivity or history of clinically significant adverse reactions to Livalo.
(4)Patients with serious hepatopathy or biliary obstruction.
(5)Patients who are being treated with cyclosporine.
(6)Pregnant, possibly pregnant, or lactating.
(7)Patients who do not accept informed consent.
(8)Patients who are judged unsuitable for this study by the doctor in charge of that patients.
30
1st name | |
Middle name | |
Last name | Maruyama Shoichi |
Nagoya University, Graduate School of Medicine
Department of Nephrology
65, TURUMAI-CHO, SHOWAKU, NAGOYA, AICHI 466-8550
052-741-2111
1st name | |
Middle name | |
Last name | Yasuda Yoshinari |
Nagoya University, Graduate School of Medicine
Department of Nephrology
65, TURUMAI-CHO, SHOWAKU, NAGOYA, AICHI 466-8550
052-741-2111
yyasuda@med.nagoya-u.ac.jp
Nagoya University, Graduate School of Medicine
None
Self funding
NO
2009 | Year | 01 | Month | 20 | Day |
Unpublished
Completed
2008 | Year | 11 | Month | 28 | Day |
2009 | Year | 02 | Month | 01 | Day |
2011 | Year | 02 | Month | 01 | Day |
2008 | Year | 12 | Month | 26 | Day |
2014 | Year | 08 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001922